The reinstatement of Amgen by Morgan Stanley with an Equal-Weight rating indicates a neutral outlook for the stock. The price target of $300 suggests that the analyst sees potential for the stock's price to reach this level. However, as this is a reinstatement and not an upgrade, it does not necessarily indicate a strong bullish sentiment, hence the neutral score.